(0.26%) 5 144.75 points
(0.29%) 38 551 points
(0.35%) 17 909 points
(-0.81%) $83.17
(1.30%) $1.948
(-0.06%) $2 345.80
(0.24%) $27.60
(0.89%) $930.30
(-0.31%) $0.932
(-0.37%) $10.98
(-0.40%) $0.797
(0.25%) $92.11
Live Chart Being Loaded With Signals
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices...
Stats | |
---|---|
本日の出来高 | 823.00 |
平均出来高 | 592.00 |
時価総額 | 174.42B |
EPS | €0 ( 2024-04-17 ) |
次の収益日 | ( €0 ) 2024-07-17 |
Last Dividend | €0.510 ( 2023-07-13 ) |
Next Dividend | €0 ( N/A ) |
P/E | 33.51 |
ATR14 | €0 (0.00%) |
Abbott Laboratories 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Abbott Laboratories 財務諸表
Annual | 2023 |
収益: | €40.11B |
総利益: | €22.13B (55.18 %) |
EPS: | €3.28 |
FY | 2023 |
収益: | €40.11B |
総利益: | €22.13B (55.18 %) |
EPS: | €3.28 |
FY | 2022 |
収益: | €43.65B |
総利益: | €24.51B (56.15 %) |
EPS: | €3.99 |
FY | 2021 |
収益: | €43.08B |
総利益: | €24.54B (56.97 %) |
EPS: | €4.00 |
Financial Reports:
No articles found.
Abbott Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.470 (N/A) |
€0.470 (N/A) |
€0.510 (N/A) |
€0.510 (N/A) |
€0.510 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.325 | 2008-01-11 |
Last Dividend | €0.510 | 2023-07-13 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | €22.13 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.9 | -- |
Div. Sustainability Score | 4.40 | |
Div.Growth Potential Score | 7.33 | |
Div. Directional Score | 5.87 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
HAW.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
RIO1.DE | Ex Dividend Knight | 2023-08-10 | Semi-Annually | 0 | 0.00% | |
BST.DE | Ex Dividend Junior | 2023-09-14 | Sporadic | 0 | 0.00% | |
JNJ.DE | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
TA1.DE | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
DEF.DE | Ex Dividend Knight | 2023-07-24 | Annually | 0 | 0.00% | |
MMM.DE | Ex Dividend Junior | 2023-08-18 | Quarterly | 0 | 0.00% | |
4I1.DE | Ex Dividend Knight | 2023-09-26 | Quarterly | 0 | 0.00% | |
VVD.DE | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% | |
EVK.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.140 | 1.500 | 7.21 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.148 | 1.500 | 9.47 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.474 | -1.000 | 5.26 | -5.26 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 22.04 | 1.000 | 2.95 | 2.95 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.50 | 2.00 | 8.83 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.45 | 2.00 | 8.77 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.552 | 1.000 | 4.13 | 4.13 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.158 | 1.000 | 8.84 | 8.84 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.40 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 33.43 | 1.000 | 6.72 | 0 | [1 - 100] |
returnOnEquityTTM | 0.148 | 2.50 | 9.66 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.45 | 2.00 | 9.18 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.971 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.50 | 2.00 | 8.83 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.474 | 1.500 | 5.26 | -5.26 | [0 - 1] |
pegRatioTTM | 6.47 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.152 | 1.000 | 8.71 | 0 | [0.1 - 0.5] |
Total Score | 7.33 |
Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。